



Cornerstone Pharmaceuticals, Inc.
1 Duncan Drive
Cranbury, NJ 08512

Media Contact: David Polinsky
Cornerstone Pharmaceuticals, Inc.
(609) 409 -7050 ext 202
news@cornerstonepharma.com

CORNERSTONE PHARMACEUTICALS ANNOUNCES SPEAKING ENGAGEMENT OF DR. PAUL BINGHAM AT THE TENTH ANNUAL DISCOVERY ON TARGET CONFERENCE IN BOSTON REGARDING CANCER CELL METABOLISM

CRANBURY, NJ (September 28, 2012) Cornerstone Pharmaceuticals, Inc. (www.cornerstonepharma.com), a leader in the growing field of cancer metabolism-based therapeutics, is pleased to announce the invitation of Paul Bingham, Ph.D., Vice President of Research, to present at the Tenth Annual Discovery On Target Conference on October 1, 2012 at the Copley Marriott Hotel in Boston, Massachusetts.

Dr. Bingham is scheduled separately as a speaker and as a moderator at the Second Annual Targeting Cancer Cell Metabolism scientific program at this conference. The details of his schedule on October 1, 2012 are as follows:

Session Title: "Lipoate Analogs: Powerful Chemotherapeutic Agents Attacking Cancer Cell Metabolism" (speaker)

Date & Time: Monday, October 1, 2012, 4:35 PM

In this session, Dr. Bingham will discuss progress on determining the mechanism and clinical anticancer efficacy of CPI-613, the lead candidate of Cornerstone's novel Altered Energy Drug Metabolism (AEMD) drug platform.

Session Title: "Challenges of Targeting the Mitochondrial Metabolism" (moderator)

Date & Time: Monday, October 1, 2012, 5:05 PM

In this interactive breakout discussion, Dr. Bingham will moderate a panel which will address many facets of cancer cell metabolism but will particularly focus on the relative merits of targeting and exploiting tumor-specific mitochondrial metabolic processes for cancer chemotherapy.

Dr. Robert Shorr, Chief Executive Officer of Cornerstone, commented "We are pleased that Dr. Bingham was invited to share his expertise at this year's Targeting Cancer Cell Metabolism conference. This is an exciting opportunity for Cornerstone Pharmaceuticals to contribute to the dialogue about tumor metabolism with respected industry and academic leaders, and we thank Dr. Bingham for agreeing to participate in this cutting-edge conference."

CPI-613, the lead drug candidate from Cornerstone's proprietary AEMD platform, disrupts biochemical alterations in the conversion of glucose to energy that occur in many types of cancer cells. These essential "bioenergetic" differences are linked to pathways that control, among other things, cancer cell



growth and development, as well as various forms of cell death, including apoptosis and necrosis. The platform is designed to produce drugs, such as CPI-613, that disrupt energy-production pathways whose organization or regulation are altered specifically in cancer cells. CPI- 613 is currently being evaluated in multiple clinical trials.

About Cornerstone Pharmaceuticals

Cornerstone Pharmaceuticals, Inc. is a privately held company that is committed to changing the way cancer is treated through the discovery and development of innovative therapies capitalizing on the unique metabolic processes of cancer cells. The company's founding members, management, and scientific advisory team include pre-eminent scientists focused on cancer cell metabolism, cancer research, and drug development. The company's unique approach to targeting cancer metabolism has led to the discovery of first-in-class drugs with the potential to transform the way cancer is treated.

###

This release contains forward-looking statements. These statements relate to future events or each company's future financial performance. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "expect", "plan", "anticipate", "believe", "estimate", "predict", "potential" or "continue", the negative of such terms, or other comparable terminology. These statements are only predictions. Actual events or results may differ materially from those in the forward-looking statements as a result of various important factors. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by the company, or any other person, that such forward looking statements will be achieved. The business and operations of the company are subject to substantial risks which increase the uncertainty inherent in forward-looking statements. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements.